European Society for Radiotherapy and Oncology shared a post on LinkedIn:
“Best Brachytherapy Paper at ESTRO26.
The 10-year results of the SiFEBI trial suggest that single-fraction brachytherapy can be a safe and effective treatment for selected elderly patients with low-risk breast cancer, with only 5% local recurrence and no cancer-related deaths.”
Other articles about European Society for Radiotherapy and Oncology on OncoDaily.